What is the progress of experimental drug development for fibromyalgia?

[1]  R. Moots,et al.  Research Recommendations Following the Discovery of Pain Sensitizing IgG Autoantibodies in Fibromyalgia Syndrome , 2021, Pain medicine.

[2]  P. Sarzi-Puttini,et al.  Fibromyalgia: an update on clinical characteristics, aetiopathogenesis and treatment , 2020, Nature Reviews Rheumatology.

[3]  S. Cuzzocrea,et al.  ALIAmides Update: Palmitoylethanolamide and Its Formulations on Management of Peripheral Neuropathic Pain , 2020, International journal of molecular sciences.

[4]  F. Zeidan,et al.  Chronic pain and psychedelics: a review and proposed mechanism of action , 2020, Regional Anesthesia & Pain Medicine.

[5]  T. Roth,et al.  Sleep and Pain in Subjects with Fibromyalgia and Comorbid Insomnia: Double-blind, Crossover, Study of Suvorexant 20 mg versus Placebo. , 2020, Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine.

[6]  Efficacy and Safety of NYX-2925 in Subjects With Fibromyalgia , 2019, Case Medical Research.

[7]  K. Lawson.  Emerging pharmacological strategies for the treatment of fibromyalgia , 2017 .

[8]  S. Skaper,et al.  Palmitoylethanolamide in Fibromyalgia: Results from Prospective and Retrospective Observational Studies , 2015, Pain and Therapy.

[9]  Takeshi Sakurai,et al.  The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness , 2007, Nature Reviews Neuroscience.

[10]  P. Sarzi-Puttini,et al.  Ultramicronized Palmitoylethanolamide (um-PEA) as add-on Treatment in Fibromyalgia Syndrome (FMS): Retrospective Observational Study on 407 Patients. , 2019, CNS & neurological disorders drug targets.